Trabectedin for advanced soft tissue sarcomas: optimizing use

about

Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Current and advancing systemic treatment options for soft tissue sarcomas.

P2860

Q36273796-4936E808-2BCA-4BBC-9962-AAC6D74942C0 Q38563242-4BE80C7A-F944-4590-B621-3882B53428F6

P2860

Trabectedin for advanced soft tissue sarcomas: optimizing use

Item

http://www.wikidata.org/entity/Q26860365

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Trabectedin for advanced soft tissue sarcomas: optimizing use

@ast

Trabectedin for advanced soft tissue sarcomas: optimizing use

@en

Trabectedin for advanced soft tissue sarcomas: optimizing use

@nl

type

Item

label

Trabectedin for advanced soft tissue sarcomas: optimizing use

@ast

Trabectedin for advanced soft tissue sarcomas: optimizing use

@en

Trabectedin for advanced soft tissue sarcomas: optimizing use

@nl

prefLabel

Trabectedin for advanced soft tissue sarcomas: optimizing use

@ast

Trabectedin for advanced soft tissue sarcomas: optimizing use

@en

Trabectedin for advanced soft tissue sarcomas: optimizing use

@nl

P1476

Trabectedin for advanced soft tissue sarcomas: optimizing use

@en

P2093

Alison Reid

http://www.w3.org/2001/XMLSchema#string

Charlotte Benson

http://www.w3.org/2001/XMLSchema#string

Juan Martin Liberal

http://www.w3.org/2001/XMLSchema#string

P2860

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

P304

1003-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S49330

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270002571

http://www.w3.org/2001/XMLSchema#string

P698

25540587

http://www.w3.org/2001/XMLSchema#string

P932

4270297

http://www.w3.org/2001/XMLSchema#string

Trabectedin for advanced soft tissue sarcomas: optimizing use

about

P2860

P2860

Trabectedin for advanced soft tissue sarcomas: optimizing use

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932